CompletedPhase 3

Ahmed Glaucoma Valve and Single-Plate Molteno Implants in Treatment of Refractory Glaucoma

Iran72 participantsStarted 2003-01

Plain-language summary

The purpose of this study is to investigate the efficacy and safety of the Ahmed valve implant (AVI) and the Molteno single-plate implant (MSPI) in eyes with refractory glaucoma during a follow-up period of 24 months.

Who can participate

Age range40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * refractory glaucoma, defined as uncontrolled IOP despite maximal anti-glaucoma medication, previously failed nonseton surgical treatment, or a combination thereof. Exclusion Criteria: * age less than 40 years * a visual acuity of no light perception * lens opacity * elevated IOP associated with silicone oil previous glaucoma drainage device implantation in the same eye * previous cyclodestructive treatment * increased risk of endophthalmitis posterior segment disorders * pre-existing ocular comorbidities.

What they're measuring

Intra Ocular pressure (IOP)

Timeframe: Month 24

Trial details

NCT IDNCT00971061

SponsorVanak Eye Surgery Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2005-08

View on ClinicalTrials.gov More Refractory Glaucoma trials